SequelSEC

BIOLARGO, INC. BLGO

Chemicals & Allied Products · CIK 0000880242 · Fiscal year ends 1231

Revenue
$7.76M
Fiscal year ended 2025-12-31
Operating income
-$14.86M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$63.07MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.20Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue8.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity41.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Chemicals & Allied Products filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio1.01x0th
Revenue YoY growth-56.3%7th
Gross margin43.9%93th
R&D / revenue33.4%90th
SBC / revenue38.2%86th
Operating margin-191.3%17th

BIOLARGO, INC. (BLGO) reported revenue of $7.76M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOLARGO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Chemicals & Allied Products.

Income

BIOLARGO, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$7.76M$17.78M$12.23M$5.88M$2.53M$2.43M$1.86M$1.36M$516.00K$281.11K
Cost of revenue$4.36M$9.93M$6.08M$3.03M$1.43M$1.20M$945.00K$743.00K$323.00K$105.88K
Gross profit$3.41M$7.85M$6.15M$2.86M$1.10M$1.23M$916.00K$621.00K$193.00K$175.23K
Operating income-$14.86M-$4.33M-$4.58M-$5.39M-$6.78M-$7.58M-$6.70M-$6.41M-$5.90M-$4.93M
Net incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Research & development$2.59M$2.88M$2.28M$1.32M$1.37M$1.34M$1.47M$1.72M$1.63M$1.38M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$15.19M-$4.35MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailable$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$11.77M$9.30M$8.06M$6.73M$6.17M$7.47M$6.14M$5.31M$4.43M$3.71M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOLARGO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$3.88M$3.55M$3.54M$1.85M$962.00K$716.00K$655.00K$655.00K$990.00K$1.91M
Total assets$8.31M$10.51M$8.20M$4.86M$3.02M$4.94M$3.62M$3.18M$1.50M$2.11M
Current assets$5.11M$7.14M$6.36M$3.15M$1.80M$1.50M$1.06M$955.00K$1.16M$2.02M
Total liabilities$6.78M$4.46M$4.00M$2.85M$2.09M$5.18M$5.80M$4.31M$4.90M$2.88M
Current liabilities$5.06M$2.65M$2.71M$1.58M$1.37M$3.54M$4.35M$2.49M$4.22M$1.15M
Total equity incl. NCI$1.53M$6.06M$4.20M$2.01M$933.00K-$235.00K-$2.18M-$1.12M-$3.41M-$770.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$310.00K$330.00K$153.00K$120.00K$241.00K$277.00K$16.00K$26.00K$54.00K$34.45K
Accounts receivable$615.00K$3.17M$2.61M$1.06M$513.00K$484.00K$355.00K$257.00K$94.00K$67.99K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$2.08M$1.08M$289.00K$237.00K$180.00K$507.00K$700.00K$1.29M$1.54M$5.25M
Accounts payable$1.01M$826.00K$1.21M$717.00K$350.00K$315.00K$195.00K$302.00K$88.00K$22.23K

Cash flow

BIOLARGO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$8.30M-$3.21M-$2.36M-$2.76M-$3.94M-$4.15M-$4.42M-$3.89M-$4.28M-$3.72M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$28.67KUnavailable
Investing cash flow$435.00K-$1.32M-$478.00K-$271.00K-$34.00K-$123.00K-$35.00K-$58.00K-$29.00K-$61.93K
Financing cash flow$8.22M$4.44M$4.66M$3.96M$4.23M$4.34M$4.47M$3.64M$3.37M$3.97M
Net change in cash$335.00K$9.00K$1.69M$889.00K$246.00K$61.00KUnavailable-$335.00K-$920.00K$147.04K
Stock-based compensation$2.96M$2.06M$2.12M$2.07M$1.87M$2.46M$1.52M$1.34M$1.10M$751.11K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$103.00K$45.00K$20.00K$58.00K$65.00K$50.00K$30.00K$13.74K

Derived

BIOLARGO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin43.9%44.2%50.3%48.6%43.6%50.5%49.2%45.5%37.4%62.3%
Operating margin-191.3%-24.4%-37.4%-91.6%-267.8%-311.8%-359.8%-470.1%-1142.6%-1755.5%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue38.2%11.6%17.4%35.2%74.0%101.1%81.8%97.9%213.8%267.2%
Current ratio1.01x2.70x2.35x2.00x1.31x0.42x0.24x0.38x0.27x1.75x
Revenue YoY growth-56.3%45.4%107.9%132.5%4.1%30.7%36.4%164.3%83.6%Unavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue33.4%16.2%18.7%22.4%54.0%55.0%79.1%126.0%315.9%491.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BLGO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.